High Purity Sermorelin: COA and FDA Status Explained

Sermorelin held FDA approval once. A sermorelin acetate injection was marketed in the United States under the brand name Geref, and it was discontinued in the late 2000s for commercial reasons rather than pulled in a safety scandal. That history is exactly why this question keeps generating confusion.

We field it constantly from lab buyers comparing sources of high purity sermorelin, and the misunderstanding is always the same shape. People assume that because a compounding pharmacy will prepare it, or because a vendor publishes a 99 percent figure on a product page, the compound must be approved. Approval, purity and availability are three completely separate things.

Is sermorelin FDA approved?

No. There is no FDA-approved sermorelin drug product currently marketed in the United States. Sermorelin acetate held approval as Geref, which was discontinued in the late 2000s. Material available today is either a pharmacy-compounded preparation or a research-use-only compound supplied with a batch certificate of analysis. Neither status equals approval.

The misconception worth killing first: a prescription is not an approval, and a purity certificate is not a regulatory clearance. A certificate of analysis speaks to the chemical identity and purity of one specific lot. Approval speaks to a finished drug product that FDA has reviewed for safety and efficacy in a defined population. What follows covers sermorelin's real regulatory history, how to read a sermorelin COA line by line, and how to qualify a supplier so the material in the vial matches the paperwork.

Where sermorelin actually stands with the FDA right now

No sermorelin product holds current FDA approval in the United States as of 2026. Sermorelin acetate, chemically GRF(1-29)NH2, is a synthetic 29-amino-acid fragment corresponding to the biologically active N-terminal region of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that signals somatotroph cells in the anterior pituitary to release growth hormone. The approved product that once carried that molecule left the market roughly two decades ago.

That withdrawal matters far more than most vendors admit, because it reshapes the compounding question. Under section 503A of the Federal Food, Drug, and Cosmetic Act, a pharmacy compounding from a bulk drug substance needs that substance to be a component of an FDA-approved drug, to have an applicable USP or NF monograph, or to appear on FDA's 503A bulk drug substances list. With no currently marketed approved product, sermorelin's eligibility runs through the bulks list route, and FDA's handling of nominated peptides has shifted over the past several years. Anyone making a purchasing or regulatory decision based on sermorelin FDA 503A status should read FDA's current bulk drug substances lists directly rather than a supplier's paraphrase of them.

Research-use-only material sits outside that framework entirely. A sermorelin research compound is supplied to laboratories for in vitro and preclinical work. It is not a drug product, it carries no approval, and it is never sold for human or veterinary consumption. When we describe high purity sermorelin, we are describing the analytical quality of a research material. Nothing more.

Reading a sermorelin certificate of analysis like a chemist

A sermorelin COA has to answer three questions: what the molecule is, how much of the sample is that molecule, and what else is in the vial. Identity comes from mass spectrometry, where measured molecular mass is matched against the theoretical mass of the GRF(1-29)NH2 sequence. Purity comes from reverse-phase HPLC, reported as the percentage of total peak area attributable to the target peptide at a stated detection wavelength. A credible sermorelin test report shows the chromatogram and the mass spectrum, not two orphan numbers in a summary table.

Here is the part almost every buying guide skips, and it is the widest gap between a purity figure and physical reality. HPLC purity describes the proportion of peptide-related material that is your sequence. It says nothing about net peptide content, which is how much of the lyophilised powder is peptide at all. The remainder is counterion (commonly acetate or trifluoroacetate), residual solvent and adsorbed water. A lot can be 99 percent pure by HPLC and still deliver meaningfully less peptide mass per vial than the gross fill weight implies, simply because water content and counterion load were never quantified. If net peptide content is missing from the sermorelin COA, the purity number is half an answer. Ask for Karl Fischer water content and, where the supplier runs it, amino acid analysis or nitrogen determination.

This is the exact point where high purity sermorelin claims either hold up or quietly collapse.

How to qualify a sermorelin peptide supplier before you order

The only certificate worth anything is batch-specific. It carries a lot number matching the number printed on your vial, a test date, the name of the analytical laboratory and the instrument method used. A generic PDF parked on a product page with no lot reference is marketing collateral, not documentation. Our team has worked through a great deal of vendor paperwork in this category, and the pattern repeats: the weakest sermorelin peptide vendor documentation is always the paperwork that cannot be tied to a physical lot.

Four checks separate a serious sermorelin peptide supplier from a reseller. Third-party analysis rather than in-house-only testing. Small-batch synthesis with verified amino-acid sequencing. Lyophilised powder handled cold with clear storage instructions. And unambiguous research-use-only labeling with no consumption language anywhere on the site. A vendor bundling a peptide with injection supplies has already told you what business it is really in.

One point deserves saying plainly. If your interest in sermorelin comes from an animal health question rather than a laboratory one, talk to your veterinarian. Research-grade material is not a veterinary medicine and is not supplied for animal use. This article is educational documentation about laboratory sourcing and analysis, not medical advice, and nothing in it describes use in humans or animals. Anyone evaluating high purity sermorelin as a sermorelin peptide product should be comparing COAs and lot records, not protocols.

High Purity Sermorelin: Sourcing Categories Compared

Buyers shopping for high purity sermorelin usually think they are choosing between vendors. They are really choosing between four distinct regulatory and documentation categories, and those differences outweigh price every time.

What If: Sermorelin Sourcing Scenarios

What if a supplier cannot produce a batch-specific COA?

Treat the lot as unqualified and keep it out of any experimental work. A certificate without a matching lot number cannot be linked to the synthesis run, the purification step or the fill that produced your vial, which means no result generated from it is traceable. Reviewers and collaborators ask for provenance, and unqualified material undermines the data before analysis begins. Request the lot-matched document before qualifying high purity sermorelin for any protocol, and if the supplier stalls, that is your answer.

What if I have read that sermorelin is linked to cancer?

No published evidence establishes that sermorelin causes cancer, and the concern originates in the wider growth hormone and IGF-1 literature rather than in sermorelin-specific data. GHRH receptor activation raises pituitary growth hormone output, which in turn raises hepatic IGF-1, and IGF-1 is a mitogenic signalling molecule. That mechanistic relationship is why clinical growth hormone therapy is approached cautiously in people with active malignancy. Searches for sermorelin side effects cancer mostly surface this theoretical reasoning, not documented causation. Research-use material carries no human safety assessment of any kind.

What if the lot number on the vial does not match the test report?

Quarantine the vial immediately and contact the supplier for the correct lot documentation before anything else happens. A mismatch usually means a document error, but it can also mean a repackaging step that broke the chain of custody between synthesis and fill. Until the discrepancy is resolved on paper, the material's purity, water content and identity are all unverified regardless of how the powder looks.

What if the lyophilised powder looks different from the previous lot?

Photograph it, document the observation and contact the supplier before reconstituting anything. Lyophilisation cake appearance varies legitimately between cycles, so a fluffier or denser plug is not automatically a defect. A collapsed, shrunken or oily-looking residue is a different signal and can indicate moisture ingress or a compromised vacuum seal, both of which accelerate peptide degradation. Visual inspection never confirms purity. Only a lot-matched analytical report does.

The Uncomfortable Truth About Peptide Purity Numbers

Let's be direct about this: a purity percentage with no chromatogram, no lot number and no test date is a marketing figure, and a large share of the sermorelin research products sold online carry exactly that. Ninety-nine percent of what, measured by which method, on which batch? Without the underlying data the number cannot be challenged, which is precisely why it gets printed. The honest version of a high purity sermorelin claim is boring by comparison: here is the lot, here is the method, here is the trace, here is the water content.

Researchers qualifying high purity sermorelin for a new study can review lot-matched documentation for our sermorelin research compound alongside the full archive of certificates of analysis, which is browsable independently of any product page. Teams comparing formats can look through the oral research compounds collection or the wider peptide catalog, and handling and fulfilment details are set out on our company information page.

High purity sermorelin is a chemistry claim, not a regulatory one, and the two get blurred in this market on purpose. A compound can be exquisitely well synthesised and still have no approved finished product standing behind it, which is exactly sermorelin's position in 2026. The question that separates good sourcing from bad is not whether a supplier uses the word pure. It is whether they hand over the lot number, the chromatogram, the mass spectrum and the water content without being asked twice. Everything else is packaging.